EUVIMEDEUVIMED entdecken
Crossref

Immune Checkpoint Inhibitor Therapy as a Novel and Effective Therapy for Aggressive Cutaneous Squamous-cell Carcinoma

Georgia M. Beasley, James Kurtz, Jeff Vandeusen, J. Harrison Howard, Alicia Terando, Doreen Agnese, David Liebner, Joanne Jeter, Thomas Olencki

Clinical Skin Cancer · 2016

DOI: 10.1016/j.clsc.2017.04.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Skin Cancer, 2016. Verfasst von Georgia M. Beasley und 8 weiteren Autor:innen. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Beasley, G. M., Kurtz, J., Vandeusen, J., Howard, J. H., Terando, A., Agnese, D., Liebner, D., Jeter, J., & Olencki, T. (2016). Immune Checkpoint Inhibitor Therapy as a Novel and Effective Therapy for Aggressive Cutaneous Squamous-cell Carcinoma. Clinical Skin Cancer. https://doi.org/10.1016/j.clsc.2017.04.001

Vancouver

Beasley GM, Kurtz J, Vandeusen J, Howard JH, Terando A, Agnese D, et al. Immune Checkpoint Inhibitor Therapy as a Novel and Effective Therapy for Aggressive Cutaneous Squamous-cell Carcinoma. Clinical Skin Cancer. 2016. doi:10.1016/j.clsc.2017.04.001

BibTeX
@article{Beasley2016,
  author = {Beasley, Georgia M. and Kurtz, James and Vandeusen, Jeff and Howard, J. Harrison and Terando, Alicia and Agnese, Doreen and Liebner, David and Jeter, Joanne and Olencki, Thomas},
  title = {Immune Checkpoint Inhibitor Therapy as a Novel and Effective Therapy for Aggressive Cutaneous Squamous-cell Carcinoma},
  journal = {Clinical Skin Cancer},
  year = {2016},
  doi = {10.1016/j.clsc.2017.04.001}
}
Kostenlos starten →